Biomarkers of drug-induced acute kidney injury: a regulatory perspective.
Biomarkers are one of the drug development tools that are being developed through collaborative efforts among multiple stakeholder communities to enhance the drug development process. Biomarkers of acute drug-induced renal injury as used in drug development are more commonly referred to as renal safety biomarkers, the focus of this manuscript. Areas covered: This manuscript provides an overview of the history and evolution of the United States Food and Drug Administration's Center for Drug Evaluation and Research's Biomarker Qualification Program. In addition, a regulatory perspective on the potential for renal safety biomarkers to accelerate medical and pharmaceutical research is presented. The first qualification submissions (acute kidney injury biomarkers) are discussed, including how the FDA review process affected the evolution of the biomarker qualification process and the future of biomarker discovery, development, and use. This manuscript also discusses a new repository for data on novel translational safety biomarkers from drug development programs. Expert opinion: In addition to the qualification of novel biomarkers, a key achievement of the first submission for qualification was the bringing together of multiple stakeholder communities to optimize the process. Early qualification reviews provided valuable lessons that informed an overarching approach of how to develop a biomarker for regulatory use.
['Blank|Melanie|M|', 'Thompson|Aliza|A|', 'Hausner|Elizabeth|E|', 'Rouse|Rodney|R|']
D058186:Acute Kidney Injury D000818:Animals D015415:Biomarkers D015195:Drug Design D064420:Drug-Related Side Effects and Adverse Reactions D006801:Humans D014481:United States D014486:United States Food and Drug Administration
biomarkers Acute kidney injury biomarker qualification drug-induced kidney injury